Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
Active, not recruiting · NCT05798507 · Registry updated 2025-12-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Active, not recruiting | Early phase 1 | 2025-12-15 | NCT05798507 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Emory University | 393 |
| National Cancer Institute (NCI) | 3015 |
| Verastem, Inc. | 24 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University Hospital/Winship Cancer Institute | Atlanta | United States | 299 |